The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer
Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic ne...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/653652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556437897740288 |
|---|---|
| author | Matthew E. Hyndman Deborah Kaye Nicholas C. Field Keith A. Lawson Norm D. Smith Gary D. Steinberg Mark P. Schoenberg Trinity J. Bivalacqua |
| author_facet | Matthew E. Hyndman Deborah Kaye Nicholas C. Field Keith A. Lawson Norm D. Smith Gary D. Steinberg Mark P. Schoenberg Trinity J. Bivalacqua |
| author_sort | Matthew E. Hyndman |
| collection | DOAJ |
| description | Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy. |
| format | Article |
| id | doaj-art-be9708d03f87459cbc869511ba880a76 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-be9708d03f87459cbc869511ba880a762025-02-03T05:45:27ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/653652653652The Use of Regenerative Medicine in the Management of Invasive Bladder CancerMatthew E. Hyndman0Deborah Kaye1Nicholas C. Field2Keith A. Lawson3Norm D. Smith4Gary D. Steinberg5Mark P. Schoenberg6Trinity J. Bivalacqua7Southern Alberta Institute of Urology, University of Calgary, Alberta, T2V 1P9, CanadaThe James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USASouthern Alberta Institute of Urology, University of Calgary, Alberta, T2V 1P9, CanadaSouthern Alberta Institute of Urology, University of Calgary, Alberta, T2V 1P9, CanadaUniversity of Chicago Medical Center, Chicago, IL 60637, USAUniversity of Chicago Medical Center, Chicago, IL 60637, USAThe James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USAThe James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USAMuscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.http://dx.doi.org/10.1155/2012/653652 |
| spellingShingle | Matthew E. Hyndman Deborah Kaye Nicholas C. Field Keith A. Lawson Norm D. Smith Gary D. Steinberg Mark P. Schoenberg Trinity J. Bivalacqua The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer Advances in Urology |
| title | The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer |
| title_full | The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer |
| title_fullStr | The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer |
| title_full_unstemmed | The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer |
| title_short | The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer |
| title_sort | use of regenerative medicine in the management of invasive bladder cancer |
| url | http://dx.doi.org/10.1155/2012/653652 |
| work_keys_str_mv | AT matthewehyndman theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT deborahkaye theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT nicholascfield theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT keithalawson theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT normdsmith theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT garydsteinberg theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT markpschoenberg theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT trinityjbivalacqua theuseofregenerativemedicineinthemanagementofinvasivebladdercancer AT matthewehyndman useofregenerativemedicineinthemanagementofinvasivebladdercancer AT deborahkaye useofregenerativemedicineinthemanagementofinvasivebladdercancer AT nicholascfield useofregenerativemedicineinthemanagementofinvasivebladdercancer AT keithalawson useofregenerativemedicineinthemanagementofinvasivebladdercancer AT normdsmith useofregenerativemedicineinthemanagementofinvasivebladdercancer AT garydsteinberg useofregenerativemedicineinthemanagementofinvasivebladdercancer AT markpschoenberg useofregenerativemedicineinthemanagementofinvasivebladdercancer AT trinityjbivalacqua useofregenerativemedicineinthemanagementofinvasivebladdercancer |